285 related articles for article (PubMed ID: 1165475)
1. Properdin- and nephritic factor-dependent C3 convertases: requirement of native C3 for enzyme formation and the function of bound C3b as properdin receptor.
Schreiber RD; Medicus RG; Gïtze O; Müller-Eberhard HJ
J Exp Med; 1975 Sep; 142(3):760-72. PubMed ID: 1165475
[TBL] [Abstract][Full Text] [Related]
2. Alternative pathway of complement: recruitment of precursor properdin by the labile C3/C5 convertase and the potentiation of the pathway.
Medicus RG; Götze O; Müller-Eberhard HJ
J Exp Med; 1976 Oct; 144(4):1076-93. PubMed ID: 978134
[TBL] [Abstract][Full Text] [Related]
3. A molecular concept of the properdin pathway.
Medicus RG; Schreiber RD; Götze O; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1976 Feb; 73(2):612-6. PubMed ID: 54923
[TBL] [Abstract][Full Text] [Related]
4. Properdin: initiation of alternative complement pathway.
Fearon DT; Austen KF
Proc Natl Acad Sci U S A; 1975 Aug; 72(8):3220-4. PubMed ID: 1059108
[TBL] [Abstract][Full Text] [Related]
5. Protection of the classical and alternative complement pathway C3 convertases, stabilized by nephritic factors, from decay by the human C3b receptor.
Fischer E; Kazatchkine MD; Mecarelli-Halbwachs L
Eur J Immunol; 1984 Dec; 14(12):1111-4. PubMed ID: 6240408
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the interactions between properdin, the third component of complement (C3), and its physiological activation products.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 May; 252(1):47-54. PubMed ID: 3421908
[TBL] [Abstract][Full Text] [Related]
7. Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase.
Fearon DT; Austen KF
J Exp Med; 1975 Oct; 142(4):856-63. PubMed ID: 1185108
[TBL] [Abstract][Full Text] [Related]
8. Complement C3 convertase: cell surface restriction of beta1H control and generation of restriction on neuraminidase-treated cells.
Pangburn MK; Müller-Eberhard HJ
Proc Natl Acad Sci U S A; 1978 May; 75(5):2416-20. PubMed ID: 276881
[TBL] [Abstract][Full Text] [Related]
9. Control of the amplification convertase of complement by the plasma protein beta1H.
Weiler JM; Daha MR; Austen KF; Fearon DT
Proc Natl Acad Sci U S A; 1976 Sep; 73(9):3268-72. PubMed ID: 1067618
[TBL] [Abstract][Full Text] [Related]
10. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins.
Fearon DT; Austen KF
J Exp Med; 1977 Jul; 146(1):22-33. PubMed ID: 559720
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
[TBL] [Abstract][Full Text] [Related]
12. C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Jan; 116(1):1-7. PubMed ID: 1245733
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the interaction between properdin and factor B, components of the alternative-pathway C3 convertase of complement.
Farries TC; Lachmann PJ; Harrison RA
Biochem J; 1988 Aug; 253(3):667-75. PubMed ID: 3140783
[TBL] [Abstract][Full Text] [Related]
14. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
[TBL] [Abstract][Full Text] [Related]
15. C3b inactivator in the rheumatic diseases. Measurement by radial immunodiffusion and by inhibition of formation of properdin pathway C3 convertase.
Whaley K; Schur PH; Ruddy S
J Clin Invest; 1976 Jun; 57(6):1554-63. PubMed ID: 819459
[TBL] [Abstract][Full Text] [Related]
16. Alternative pathway of complement: demonstration and characterization of initiating factor and its properdin-independent function.
Schreiber RD; Götze O; Müller-Eberhard HJ
J Exp Med; 1976 Oct; 144(4):1062-75. PubMed ID: 62010
[TBL] [Abstract][Full Text] [Related]
17. C3 requirements for formation of alternative pathway C5 convertase.
Daha MR; Fearon DT; Austen KF
J Immunol; 1976 Aug; 117(2):630-4. PubMed ID: 950465
[TBL] [Abstract][Full Text] [Related]
18. The natural modulation of the amplification phase of complement activation.
Fearon DT; Daha MR; Weiler JM; Austen KF
Transplant Rev; 1976; 32():12-25. PubMed ID: 62426
[TBL] [Abstract][Full Text] [Related]
19. The conversion of human complement component C5 into fragment C5b by the alternative-pathway C5 convertase.
DiScipio RG
Biochem J; 1981 Dec; 199(3):497-504. PubMed ID: 6918218
[TBL] [Abstract][Full Text] [Related]
20. Novel Assays to Distinguish Between Properdin-Dependent and Properdin-Independent C3 Nephritic Factors Provide Insight Into Properdin-Inhibiting Therapy.
Michels MAHM; van de Kar NCAJ; van den Bos RM; van der Velden TJAM; van Kraaij SAW; Sarlea SA; Gracchi V; Oosterveld MJS; Volokhina EB; van den Heuvel LPWJ
Front Immunol; 2019; 10():1350. PubMed ID: 31263464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
